AnaptysBio (ANAB) Stock: Buy, Sell, or Hold?
ANAB - AnaptysBio, Inc. Common Stock
$48.10
0.16 (0.33%)
▲
5d:
-1.25%
30d:
-5.26%
90d:
-11.17%
BUY
HIGH Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 03, 2026
10d
Get Alerted When ANAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ANAB trading at deep discount. Market pricing in -4.4% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: ANAB trading at deep discount. Market pricing in -4.4% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$89.63
Based on 10.3% avg growth
INTRINSIC VALUE TODAY
$55.65
13.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ANAB is currently trading at $48.10, which is considered slightly low relative to its 30-day fair value range of $46.55 to $53.00. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.5) compared to its historical average (10.9). Remarkably, the market is currently pricing in an annual earnings decline of 4.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ANAB is in a downtrend. Immediate support is located at $44.02, while resistance sits at $51.85.
Market Sentiment: ANAB scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (27th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $87.25 (+81.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ANAB is in a downtrend. Immediate support is located at $44.02, while resistance sits at $51.85.
Market Sentiment: ANAB scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (27th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $87.25 (+81.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$46.55 -
$53.00
Company Quality Score
53/100
(HOLD)
Options IV Signal
27th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
92.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 27th percentile)
- BULLISH: Strong technical setup (70/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 81.4% below Wall St target ($87.25)
- BULLISH: Bottoming setup score 70/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$46.55 -
$53.00
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$6.07
(12.6%)
Support & Resistance Levels
Support Level
$44.02
Resistance Level
$51.86
Current Trend
Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.49
Wall Street Target
$87.25
(+81.4%)
Revenue Growth (YoY)
23.5%
Profit Margin
247.0%
Valuation Discount vs History
-4.4% cheaper
PE vs Historical
9.5 vs 10.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.4%
(market-implied from PE analysis)
1-Year Target
$45.98
(-4%)
2-Year Target
$43.96
(-9%)
3-Year Target
$42.03
(-13%)
3-Yr Target (if PE normalizes)
(PE: 9→11)
$48.27
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 16.5%)
$159.17
(+231%)
Base:
(SPY PE: 9.5, Growth: 16.5%)
$76.06
(+58%)
Bear:
(PE: 8.1, Growth: 16.5%)
$64.65
(+34%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.5 to 10.9
Stabilization Target:
$55.24
(+14.9%)
PE Expansion Potential:
+14.9%
Share & Embed Analysis
Last updated: October 23, 2026 7:42 AM ET
Data refreshes hourly during market hours. Next update: 8:42 AM
Data refreshes hourly during market hours. Next update: 8:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 59 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 56 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 49 HOLD |
|
TRVI
Trevi Therapeutics Inc |
STRONG BUY
11 analysts |
$28 | 69 BUY |